// App-Quantinova.ai

OP0286 (2022) : DEVELOPMENT AND PRELIMINARY VALIDATION OF THE SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR): A CONSENSUAL COMPOSITE SCORE FOR ASSESSING TREATMENT EFFECT IN PRIMARY SJÖGREN’S SYNDROME

Researchers

Presenter

  • R. Seror

Principal Investigators

  • G. Baron

  • M. Camus

  • D. Cornec

  • E. Perrodeau

  • S. J. Bowman

  • M. Bombardieri

  • H. Bootsma

  • J. E. Gottenberg

  • B. Fisher

  • W. Hueber

  • J. van Roon

  • V. Devauchelle-Pensec

  • P. Gergely

  • X. Mariette

  • R. Porcher

Medical Centers

  • Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Rheumatology, Le Kremlin Bicêtre, France

  • Université Paris-Saclay, INSERM UMR1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France

  • Assistance Publique-Hôpitaux de Paris, Hôtel Dieu Hospital, Statistics, Paris, France

  • Université Paris Descartes Sorbonne Paris Cité, INSERM U1153, Centre of Research in Epidemiology and StatisticS, Paris, France

  • CHU Brest, Rheumatology, Brest, France

  • Université de Brest, UMR1227, Inserm, LBAI, Brest, France

  • Milton Keynes University Hospital, Milton Keynes, United Kingdom

  • University Hospitals Birmingham and University of Birmingham, Rheumatology, Birmingham, United Kingdom

  • William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom

  • University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, Netherlands

  • Chu Strasbourg, Rhumatologie, Strasbourg, France

  • CNRS, UPR3572, Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire, Centre National de Référence pour les Maladies Auto-Immunes Systémiques Rares, Strasbourg, France

  • University Hospitals Birmingham NHS Foundation Trust, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Rheumatology Research Group, Birmingham, France

  • University of Birmingham, Institute of Inflammation and Ageing, Birmingham, UK

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

  • University Medical Center Utrecht, Utrecht University, Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, Utrecht, Netherlands

  • Novartis Institutes for BioMedical Research, Basel, Switzerland

  • Assistance Publique-Hôpitaux de Paris, Hôtel Dieu Hospital, Centre d’épidémiologie clinique, Paris, France

Locations

  • France

  • United Kingdom

  • Netherlands

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

  • STAR syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • GlaxoSmithKline (GSK) and Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved